Recent results have cast doubt over how effective a breakthrough class of cystic fibrosis drugs can be in patients with the most common form of the disease.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Rights and permissions
About this article
Cite this article
Holmes, D. False dawn for cystic fibrosis disease modifiers?. Nat Rev Drug Discov 13, 713–714 (2014). https://doi.org/10.1038/nrd4456
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd4456
This article is cited by
-
Vertex combo scores a broader cystic fibrosis approval
Nature Reviews Drug Discovery (2015)
